| Trial ID: | L3839 |
| Source ID: | NCT01394510
|
| Associated Drug: |
N-Acetylcysteine
|
| Title: |
Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01394510/results
|
| Conditions: |
Type 2 Diabetes|Oxidative Stress
|
| Interventions: |
DRUG: N-acetylcysteine
|
| Outcome Measures: |
Primary: Fasting Urine F2 Alpha Isoprostane Levels, Change in fasting urine isoprostane levels at 4 weeks vs baseline as a marker of oxidative stress, 4 weeks | Secondary: Area Under the Curve for Glucose (AUCg), Change in AUCg from 0-120 minutes during the oral glucose tolerance test at 4 weeks compared to baseline, 4 weeks|Oral Disposition Index, The change in the oral disposition index defined was the change in the early insulin response divided by the change in glucose from 0-30 minutes during the oral glucose tolerance test divided by fasting insulin., 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: Utzschneider, Kristina, M.D. | Collaborators: VA Puget Sound Health Care System
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
13
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2011-06
|
| Completion Date: |
2015-12
|
| Results First Posted: |
2016-06-17
|
| Last Update Posted: |
2016-06-17
|
| Locations: |
VA Puget Sound Health Care System, Seattle, Washington, 98108, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01394510
|
